Total Payments
$1,768
2024 Payments
$276.68
Companies
15
Transactions
31
Medicare Patients
4,698
Medicare Billing
$587,680
Payment Breakdown by Category
Food & Beverage$1,354 (76.6%)
Travel$413.76 (23.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,354 | 29 | 76.6% |
| Travel and Lodging | $413.76 | 2 | 23.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Medtronic USA, Inc. | $623.57 | 6 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $269.46 | 3 | $0 (2024) |
| ABBVIE INC. | $249.12 | 9 | $0 (2024) |
| Grifols USA, LLC | $161.25 | 1 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $120.05 | 1 | $0 (2024) |
| Boston Scientific Corporation | $87.08 | 1 | $0 (2023) |
| GlaxoSmithKline, LLC. | $75.27 | 1 | $0 (2022) |
| Vapotherm Inc | $51.36 | 1 | $0 (2020) |
| BioDelivery Sciences International, Inc. | $29.78 | 2 | $0 (2021) |
| HARTMANN USA, INC. | $21.79 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $276.68 | 4 | E.R. Squibb & Sons, L.L.C. ($120.05) |
| 2023 | $512.08 | 6 | Grifols USA, LLC ($161.25) |
| 2022 | $112.85 | 3 | GlaxoSmithKline, LLC. ($75.27) |
| 2021 | $191.02 | 11 | AbbVie Inc. ($60.62) |
| 2020 | $51.36 | 1 | Vapotherm Inc ($51.36) |
| 2019 | $623.57 | 6 | Medtronic USA, Inc. ($623.57) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: ONCOLOGY | ||||||
| 08/19/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE, AVYCAZ | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/16/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $120.05 | General |
| Category: Cardiovascular | ||||||
| 01/18/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $116.55 | General |
| Category: Respiratory | ||||||
| 11/02/2023 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $161.25 | General |
| Category: Pulmonology | ||||||
| 11/02/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $20.44 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/07/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $39.37 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/29/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $90.40 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/30/2023 | Boston Scientific Corporation | WATCHMAN Access System (Device) | Food and Beverage | In-kind items and services | $87.08 | General |
| Category: WATCHMAN_IC | ||||||
| 05/04/2023 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $113.54 | General |
| Category: Respiratory | ||||||
| 02/28/2022 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/01/2022 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $18.53 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/13/2022 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $75.27 | General |
| 12/02/2021 | AbbVie Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $26.38 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/29/2021 | HARTMANN USA, INC. | Two Press (Device) | Food and Beverage | Cash or cash equivalent | $21.79 | General |
| Category: Wound Care | ||||||
| 09/29/2021 | AbbVie Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/22/2021 | Dynavax Technologies Corporation | Heplisav-B (Drug) | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: Hepatitis B Vaccine | ||||||
| 08/31/2021 | BioDelivery Sciences International, Inc. | BELBUCA (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Chronic Pain | ||||||
| 08/30/2021 | PFIZER INC. | PANZYGA (Biological), CUTAQUIG | Food and Beverage | In-kind items and services | $19.53 | General |
| Category: IMMUNOLOGY;INFLAMMATION | ||||||
| 08/26/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/26/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $14.86 | General |
| Category: Diabetes | ||||||
| 06/28/2021 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $11.89 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/14/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $20.75 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 04/02/2021 | BioDelivery Sciences International, Inc. | BELBUCA (Drug) | Food and Beverage | In-kind items and services | $11.58 | General |
| Category: Chronic Pain | ||||||
| 02/07/2020 | Vapotherm Inc | Precision Flow (Device) | Food and Beverage | In-kind items and services | $51.36 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 838 | 1,157 | $181,101 | $95,698 |
| 2022 | 10 | 884 | 1,196 | $212,038 | $111,911 |
| 2021 | 10 | 1,451 | 2,014 | $342,649 | $188,362 |
| 2020 | 11 | 1,525 | 2,173 | $366,625 | $191,710 |
Total Patients
4,698
Total Services
6,540
Medicare Billing
$587,680
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 68 | 159 | $43,187 | $21,967 | 50.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 187 | 209 | $40,513 | $21,966 | 54.2% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2023 | 202 | 272 | $31,173 | $16,514 | 53.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 98 | 138 | $16,056 | $8,814 | 54.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 54 | 68 | $12,040 | $6,459 | 53.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 35 | $9,798 | $4,690 | 47.9% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 87 | 117 | $8,411 | $4,654 | 55.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 22 | 22 | $7,365 | $3,886 | 52.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 15 | 23 | $4,448 | $2,386 | 53.6% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 59 | 90 | $4,210 | $2,294 | 54.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 11 | 24 | $3,900 | $2,067 | 53.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 93 | 209 | $49,248 | $29,201 | 59.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 244 | 272 | $57,664 | $29,117 | 50.5% |
| 99497 | Advance care planning, first 30 minutes | Facility | 2022 | 228 | 283 | $37,332 | $17,686 | 47.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 57 | 57 | $18,313 | $9,521 | 52.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 101 | 150 | $16,800 | $8,444 | 50.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 56 | $9,534 | $5,452 | 57.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 50 | 65 | $10,530 | $5,342 | 50.7% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 15 | 35 | $4,025 | $2,917 | 72.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 20 | $6,240 | $2,911 | 46.7% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 44 | 49 | $2,352 | $1,318 | 56.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 387 | 434 | $92,008 | $47,868 | 52.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 111 | 293 | $65,925 | $43,115 | 65.4% |
| 99497 | Advance care planning by the physician or other qualified health care professional, first 30 minutes | Facility | 2021 | 360 | 456 | $60,192 | $29,224 | 48.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 255 | 418 | $46,816 | $24,506 | 52.3% |
About Benjamin Goldstein
Benjamin Goldstein is a Geriatric Medicine healthcare provider based in Cumberland, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/01/2014. The National Provider Identifier (NPI) number assigned to this provider is 1578978383.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Benjamin Goldstein has received a total of $1,768 in payments from pharmaceutical and medical device companies, with $276.68 received in 2024. These payments were reported across 31 transactions from 15 companies. The most common payment nature is "Food and Beverage" ($1,354).
As a Medicare-enrolled provider, Goldstein has provided services to 4,698 Medicare beneficiaries, totaling 6,540 services with total Medicare billing of $587,680. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Geriatric Medicine
- Other Specialties Student in an Organized Health Care Education/Training Program, Hospice and Palliative Medicine
- Location Cumberland, MD
- Active Since 07/01/2014
- Last Updated 01/25/2024
- Taxonomy Code 207RG0300X
- Entity Type Individual
- NPI Number 1578978383
Products in Payments
- OSTEOCOOL RF ABLATION (Device) $623.57
- TEZSPIRE (Biological) $230.09
- Prolastin-C Liquid (Biological) $161.25
- AVYCAZ (Drug) $145.95
- ELIQUIS (Drug) $120.05
- WATCHMAN Access System (Device) $87.08
- Precision Flow (Device) $51.36
- TEFLARO (Drug) $46.80
- FARXIGA (Drug) $39.37
- DALVANCE (Drug) $36.71
- BELBUCA (Drug) $29.78
- Two Press (Device) $21.79
- XARELTO (Drug) $20.75
- VENCLEXTA (Drug) $19.66
- PANZYGA (Biological) $19.53
- Ozempic (Drug) $14.86
- ENTRESTO (Drug) $11.89
- Heplisav-B (Drug) $11.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.